MUNICH, Germany, October 1 /PRNewswire/ --
- New Product Under Development for the Treatment of High Blood
- Approval Requested in 28 European Countries
DAIICHI SANKYO EUROPE GmbH has applied in 28 European countries for
approval of a new antihypertensive medication. It is a fixed combination
(CS-8663) of two substances, the angiotensin receptor blocker (ARB)
Olmesartan and the calcium antagonist Amlodipin.
When approved, the new combination for treatment of essential
hypertension is designed for use in patients whose blood pressure cannot be
adequately controlled through therapy with the respective monopreparation.
In clinical trials the combination of Olmesartan / Amlodipin (CS-8663) has
shown a significant lowering of blood pressure. In the new fixed
combination, two complementary therapeutic approaches are combined:
blocking of the angiotensin II receptor and blocking of the calcium
channel. Olmesartan is already being marketed by DAIICHI SANKYO and is the
angiotensin receptor blocker with the greatest sales growth in Europe(1).
Amlodipin is one of the most frequently used calcium antagonists in many
"Hypertension is currently viewed as the number one cause of death.
Most patients need two or even more medications to normalise their blood
pressure. The new fixed combination has proved to be effective and well
tolerated in a large number of patients. That also applies to patients who
have very high blood pressure at the start of therapy," says Dr Petra
Laeis, Head of Clinical Research at DAIICHI SANKYO EUROPE. "The combination
of the two well-known agents Olmesartan and Amlodipin in one tablet gives
doctors another effective treatment option for hypertension, which can lead
to better results because patients are more likely to use it faithfully,"
continues Dr Laeis.
DAIICHI SANKYO is a worldwide, research-oriented pharmaceutical
company, created through the merger of the two traditional Japanese
enterprises Daiichi and Sankyo. The company is one of the world's leading
manufacturers of medication. The company's research activities focus on the
areas of cardiovascular, haematology, diabetes, anti-infectives and cancer.
DAIICHI SANKYO has its European headquarters in Munich.
For additional information, please visit our website at
(1) Source: IMS MIDAS Juli 2007
Dr Andrea Jager
Vice Director Operative Marketing
SOURCE DAIICHI SANKYO EUROPE GmbH